Citius Pharmaceuticals, Inc. (CTXR) vs Estrella Immunopharma, Inc. (ESLA)
A side-by-side comparison of Citius Pharmaceuticals, Inc. and Estrella Immunopharma, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CTXR
Citius Pharmaceuticals, Inc.
$0.52HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
ESLA
Estrella Immunopharma, Inc.
$0.44HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
Total return — CTXR vs ESLA
growth of $100 · dividends reinvested · last 5yCTXR -99.0% (-60.2%/yr)ESLA -95.5% (-46.2%/yr)ESLA compounded faster over this window
CTXR ESLA
CTXR vs ESLA: by the numbers
- •ESLA is the larger company ($19M vs $14M market cap).
- •Both run net losses; ESLA's is the smaller (0.00% vs -651.27% net margin).
Metrics side by side
Valuation
| Metric | CTXR | ESLA |
|---|---|---|
| P/S ratio | 2.01 | N/A |
| P/B ratio | 0.21 | N/A |
Profitability
| Metric | CTXR | ESLA |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | -651.27% | 0.00% |
| ROE | -69.47% | N/A |
| ROIC | -67.62% | N/A |
Growth (annualized)
| Metric | CTXR | ESLA |
|---|---|---|
| Total return CAGR (5Y) | -60.04% | -46.34% |
Frequently asked
- How have CTXR and ESLA total returns compared?
- Over the past 5 years, CTXR delivered -60.04% and ESLA delivered -46.34% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.